Published in JOP on July 05, 2010
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol (2012) 2.38
Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis (2011) 1.18
Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma. Medicine (Baltimore) (2016) 0.78
ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma. Medicine (Baltimore) (2016) 0.75
Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. JOP (2008) 2.39
The impact of sestamibi scanning on the outcome of parathyroid surgery. J Clin Endocrinol Metab (2003) 1.57
Screening for early pancreatic ductal adenocarcinoma: an urgent call! JOP (2009) 1.57
Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. World J Gastroenterol (2009) 1.55
Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer (2009) 1.44
Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases. JOP (2009) 1.43
Platinum-based therapy in adenosquamous pancreatic cancer: experience at two institutions. JOP (2014) 1.39
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.38
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs (2007) 1.30
Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J Support Oncol (2007) 1.29
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res (2006) 1.29
Pancreatic neoplasm in 2011: an update. JOP (2011) 1.28
Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs (2010) 1.18
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs (2006) 1.17
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol (2007) 1.16
Cancers of the appendix: review of the literatures. ISRN Oncol (2011) 1.07
Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature. JOP (2007) 1.06
1112 consecutive bilateral neck explorations for primary hyperparathyroidism. World J Surg (2007) 1.05
Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs (2010) 1.04
Primary squamous cell carcinoma of the liver. J Gastrointestin Liver Dis (2009) 1.03
Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J Immunol (2007) 1.02
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs (2009) 1.02
Treatment of locally advanced pancreatic cancer: the role of radiation therapy. Int J Radiat Oncol Biol Phys (2011) 1.02
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? Clin Colorectal Cancer (2009) 1.02
Advancements in the management of pancreatic cancer: 2013. JOP (2013) 1.02
Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP (2007) 1.00
Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol (2013) 1.00
Capecitabine and hand-foot syndrome. Expert Opin Drug Saf (2010) 0.99
Gastrointestinal stromal tumors of the pancreas. JOP (2010) 0.98
Hypersensitivity vasculitis associated with leuprolide (Lupron). Cutan Ocul Toxicol (2010) 0.96
IGF system in cancer: from bench to clinic. Anticancer Drugs (2011) 0.96
Three-drug combination regimen in pancreatic cancer treatment: are we there yet? JOP (2011) 0.96
Supportive and palliative care of pancreatic cancer. JOP (2007) 0.95
Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother (2013) 0.94
Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer. JOP (2008) 0.93
Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP (2007) 0.93
FOLFIRINOX: from the ACCORD study to 2014. JOP (2014) 0.91
Peritoneal mesothelioma. Curr Treat Options Oncol (2008) 0.91
Pulmonary thromboembolism in AIDS patient with chronic venous insufficiency, pulmonary tuberculosis and breast cancer: a case report and pathophysiology review. Rev Inst Med Trop Sao Paulo (2006) 0.90
Chemotherapy: Metastatic pancreatic cancer--is FOLFIRINOX the new standard? Nat Rev Clin Oncol (2011) 0.90
Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res (2010) 0.89
Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer (2011) 0.89
Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs (2011) 0.89
Pulmonary toxicity associated with gemcitabine. JOP (2010) 0.89
Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP (2007) 0.89
Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol (2010) 0.88
Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol (2011) 0.87
Expectoration of a lung metastasis in a patient with colorectal carcinoma. Clin Colorectal Cancer (2008) 0.87
Early detection of pancreatic cancer. JOP (2012) 0.87
Contribution of obesity to pancreatic carcinogenesis. Surg Obes Relat Dis (2008) 0.87
Medullary carcinoma of the colon: a case series and review of the literature. In Vivo (2014) 0.87
Heat shock protein inhibitors and vaccines as new agents in cancer treatment. Expert Opin Investig Drugs (2009) 0.87
Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP (2009) 0.87
Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. JOP (2013) 0.86
Quality of life in patients with pancreatic cancer. JOP (2012) 0.86
Gemcitabine-induced pulmonary toxicity. Anticancer Res (2012) 0.86
Update on novel therapies for pancreatic neuroendocrine tumors. JOP (2012) 0.86
Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP (2008) 0.85
Pancreatic neuroendocrine tumors: entering a new era. JOP (2012) 0.85
Nutritional status of patients with locally advanced pancreatic cancer: a pilot study. Support Care Cancer (2010) 0.85
Secondary tumors of the pancreas: a case series. Anticancer Res (2012) 0.85
Pancreatic adenocarcinoma with supraclavicular lymph node metastasis: is this the Virchow's node? JOP (2011) 0.85
Management of borderline resectable pancreatic adenocarcinoma. JOP (2012) 0.84
Cutaneous metastasis in a patient with pancreatic cancer. JOP (2011) 0.84
Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev (2008) 0.84
Metastatic cervical carcinoma to the thyroid gland: a case report and review of the literature. Yale J Biol Med (2006) 0.84
Advancements in the management of pancreatic cancer. JOP (2009) 0.83
Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): epidemiology, diagnosis and future aspects. JOP (2013) 0.83
PARP-inhibitors in BRCA-associated pancreatic cancer. JOP (2014) 0.83
Adjuvant therapy for pancreatic cancer. JOP (2014) 0.83
Diabetes and pancreatic cancer. JOP (2014) 0.83
First-line treatment for advanced pancreatic cancer. JOP (2013) 0.83
Updates in locally advanced pancreatic cancer. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.83
Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007. JOP (2007) 0.82
Locally advanced pancreatic adenocarcinoma: update and progress. JOP (2012) 0.82
Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. Ther Adv Med Oncol (2012) 0.82
Role of anticoagulation in the management of pancreatic cancer. JOP (2009) 0.82
The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver (2010) 0.82
Biomarkers in neuroendocrine tumors. JOP (2013) 0.82
Small intestine bacterial overgrowth: an underdiagnosed cause of diarrhea in patients with pancreatic cancer. JOP (2009) 0.82
Metastatic pancreatic cancer: the dilemma of quality vs. quantity of life. JOP (2013) 0.81
Novel treatment approaches for locally advanced pancreatic cancer. JOP (2014) 0.81
Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors. JOP (2014) 0.81
Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect? Clin Colorectal Cancer (2009) 0.81
Advancements in the Management of Pancreatic Cancer: 2015 ASCO Gastrointestinal Cancers Symposium (San Francisco, CA, USA. January 15-17, 2015). JOP (2015) 0.81